3Keeley EC,Boura JA,Grines CL.Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction:a quantitative revicw of 23 randomised trials.Lancet,2003,361:13-20.
4Zijlstra F,Hoorntje JC,De Boer M J,et al.Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction.N Engl J Med,1999,341:1413-1419.
5Antoniucci D,Rodriguez A,Hempel A,et al.A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.J Am Coll Cardiol,2003,42:1879-1885.
7Krumholz HM,Anderson JL,Brooks NH,et al.ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction:a report of the ACC/AHA Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction).Circulation,2006,113:732-761.
8Mehran R,Rao SV,Bhatt DL,et al.Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium.Circulation,2011,123:2736-2747.
9Kimmelstiel C,Zhang P,Kapur NK,et al.Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.Circ Cardiovasc Interv,2011,4:171-179.
10Lincoff AM,Bittl JA,Harrington RA,et al.Bivalirudin and provisional glycoprotein Ⅱ b/ Ⅲ a blockade compared with heparin and planned glycoprotein Ⅱ b/ Ⅲ a blockade during percutaneous coronary intervention:REPLACE-2 randomized trial.JAMA,2003,289:853-863.
